Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 1050-1057

  Thomson, Alison H ^a,b,e   Staatz, C E ^a,b   Tobin, C M ^c   Gall, M ^d   Lovering, A M ^c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antimicrobial agents; Population pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

VANCOMYCIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; PRACTICE GUIDELINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, THEORETICAL; PLASMA; VANCOMYCIN; YOUNG ADULT;

EID: 64649094855     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp085     Document Type: Article

References (45)

1. Tobin CM, Darville JM, Thomson AH et al. Vancomycin therapeutic drug monitoring (TDM): Is there a consensus view? The results of a UK National External Quality Assessment Scheme for Antibiotic Assays (UK NEQAS) questionnaire. J Antimicrob Chemother 2002; 50: 713-8.
2. Helgason KO, Thomson AH, Ferguson C. A review of vancomycin therapeutic drug monitoring recommendations in Scotland. J Antimicrob Chemother 2008; 61: 1398-9.
3. Joint Formulary Committee. British National Formulary, Fifty-sixth Edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, September 2008.
4. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
5. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267-84.
6. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomised study. Antimicrob Agents Chemother 2001; 45: 2460-7.
7. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608.
8. Elting LS, Rubenstein EB, Kurtin D et al. Mississippi mud in the 1990s: Risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998; 83: 2597-607.
9. Rybak MJ, Albrecht LM, Bolke SC et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-97.
10. Lodise TP, Lomaestro B, Graves J et al. Larger vancomycin doses (at least 4 grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6.
11. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infection. Efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
12. Jeffres MN, Isakow W, Doherty JA et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107-15.
13. Ingram PR, Lye DC, Tambyah PA et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008; 62: 168-71.
14. Moellering RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: A nomogram for dosage. Ann Intern Med 1981; 94: 343-6.
15. Matzke GR, McGory RW, Halstenson CE et al. Pharmacokinetics of vancomycin in patients with varying degrees of renal function. Antimicrob Agents Chemother 1984; 25: 433-7.
16. Karam CM, MvKinnon PS, Neuhauser MN et al. Outcome assessment of minimising vancomycin monitoring and dosing adjustments. Pharmacotherapy 1999; 19: 257-66.
17. Lake KD, Peterson CD. Evaluation of a method for initiating vancomycin therapy: Experience in 205 patients. Pharmacotherapy 1988; 8 284-6.
18. Staatz CE, Byrne C, Thomson AH. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. Br J Clin Pharmacol 2006; 61 164-76.
19. James W. Research on Obesity. London: Her Majesty's Stationery Office, 1976.
20. Janmahasatian S, Duffull SB, Ash S et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
21. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8 650-5.
22. Du Bois D, Du Bois EF. Clinical calorimetry. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-71.
23. Rosario MC, Thomson AH, Jodrell DI et al. Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 1998; 46: 229-36.
24. Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
25. Jelliffe R. Creatinine clearance: Bedside estimate. Ann Intern Med 1973; 79: 604-5.
26. Salazar D, Corcoran G. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat free body mass. Am J Med 1988; 84: 1053-60.
27. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-70.
28. Beal SL, Sheiner LB, Boeckmann AJ, eds. NONMEM® Users Guides. Ellicott City, Maryland, USA: Icon Development Solutions, 1989-2006.
29. Lindblom L, Pihlgren P, Jonsson EN. PsN-toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79 241-57.
30. Jonsson N, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
31. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2008. http://www.R-project.org (28 January 2009, date last accessed).
32. Elfron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman and Hall, 1993.
33. Yasuhara M, Ig T, Zenda H et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit 1998; 20 139-48.
34. Buelga DS, del Mar Fernadez de Gatta M, Herrera EV et al. Population pharmacokinetic analysis of vancomycin in patients with haematological malignancies. Antimicrob Agents Chemother 2005; 49: 4934-41.
35. Llopis-Salvia P, Jiménez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther 2006; 31: 447-54.
36. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: Effect of age, gender, and body weight. Ther Drug Monit 1994; 16: 513-8.
37. Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with varying degrees of renal function. Antimicrob Agents Chemother 1988; 32: 848-52.
38. del Mar Fernández de Gatta Garcia M, Revilla N, Calvo MV et al. A pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33: 279-85.
39. Vance-Bryan K, Guay DRP, Gilliland SS et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37: 436-40.
40. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621-5.
41. Blouin RA, Bauer LA, Miller DD et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-80.
42. Rybak M, Lomaestro B, Rotschaefer JC et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
43. Pea F, Porreca L, Baraldo M et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45: 329-35.
44. Moise-Broder PA, Forrest A, Birmingham M et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42.
45. Wang J, Fang C, Chen Y et al. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 2001; 47: 239-46.